Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an announcement.
RemeGen Co., Ltd. has completed a share repurchase plan for its A-shares on the Shanghai Stock Exchange, using RMB20 million of its own and/or self-raised funds to buy back 194,144 shares, or 0.0344% of its total share capital, via centralized bidding. The board had previously approved the plan with a funding range of RMB20 million to RMB40 million and later raised the maximum repurchase price from RMB95 to RMB116 per share to reflect confidence in the company’s long-term value and market conditions, with the actual buyback executed at prices between RMB102.17 and RMB103.78 per share; the repurchased shares are earmarked for future employee stock ownership or equity incentive schemes, and the company said the transaction will not materially affect its operations, financial position, control structure, or listing status.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$99.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company listed in Hong Kong and the Chinese A-share market, focused on developing and commercializing innovative therapies, with its capital market strategy including active use of share repurchase and equity incentive tools to support long-term growth and employee alignment.
Average Trading Volume: 5,134,967
Technical Sentiment Signal: Buy
Current Market Cap: HK$62.53B
See more data about 9995 stock on TipRanks’ Stock Analysis page.